Create your personal agenda –check the favourite icon
Workshop A [Room: Constellation A]
WVIC - Next Generation Vaccine Adjuvants Workshop - Constellation A
2pm: Chair opening remarks: Rebecca Kurnat M.S., Head of Product, SaponiQx
Presentations: 2.10pm – 4.00pm:
Using synthetic biology in adjuvant technology & creating a pipeline of vaccine adjuvants
Dr John Baldoni, Head of Science, SaponiQx
Next generation TLR agonists & RIG-I as adjuvants
Dr Steve Reed, CEO, HDT Bio
An oral adjuvant to augment vaccine effectiveness
Dr Upendra Marathi, President & CEO, 7Hills Pharma
Long-lasting germinal center responses to a priming immunization with continuous proliferation and somatic mutation
Dr Harry Sutton, Post-doctoral Fellow, Center for Infectious Disease and Vaccine Research, LaJolla Institute for Immunology
4.00-5:00pm Q&A and Panel Discussion with all speakers
- What are the limitations of current adjuvants?
- Importance of unique formulations & combination adjuvants
- Kinetics, localization, dose sparing
- Ensuring a secure supply of known adjuvants
- Rapid response and stockpiling
- Emerging concepts in adjuvant science
- What mechanisms are required to advance vaccines?
- Novel adjuvant technology – synthetic adjuvants
- Development of an adjuvant pipeline – can new adjuvants rescue previously failed vaccines?
- What factors drive clinical failure?
Workshop B [Room: Constellation B]
WAC - Antibody Drug Discovery For Infectious Disease Workshop - Constellation B
Antibody Drug Discovery for Infectious Diseases
2pm – 5pm
2pm: Chair opening remarks:Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology
Presentations 2.10pm – 4pm:
Shark-derived nanobodies for diagnostic and therapeutic use
Dr Helen Dooley, Assistant Professor, University of Maryland School of Medicine
Developing high affinity, high avidity, IgM antibodies for the prevention and treatment of infectious diseases
Dr Sha Ha, VP, CMC, IGM Biosciences
Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants
Dr Shivshankar “Shankar” Sundaram, Director, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus
Dr Haoyang Li, Instructor, Center for Infectious Disease and Vaccine Research
La Jolla Institute for Immunology, LaJolla Institute
Tackling viral infections by human monoclonal antibodies
Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology
4.00-5:00pm Panel & Q&A with speakers: Overcoming hurdles in antibodies discovery and development against viral infection
- How to develop antibodies that are resistant to viral mutations?
- How can the cost be justified if other therapeutics are available?
- What effects has the pandemic had in increasing desire for therapeutic antibodies
- The role of FC and FC modifications to enhance effector function
Create your personal agenda –check the favourite icon
Welcome to the congress
WVIC - Plenary - Constellation A&B
Opening keynote presentation: Integrated Pandemic Preparedness
WVIC - Plenary - Constellation A&B
- How vaccines, monoclonals, direct acting antiviral, agents targeting host factors have essential roles in mounting a broad, response to future pandemics
- The need to develop and validate assays for detection of infection and measurement of immunity
Panel: HIV – how can we end the epidemic?
WVIC - Plenary - Constellation A&B
li>- How is new research bringing the goal of a cure within reach?
- HIV Vaccine, antibody, and antiviral landscape
- Merits / potential of different approaches – mRNA, bNAbs, LAAV, pre-exposure prophylaxis, prophylactic vs therapeutic vaccineso How are we defining functional cure?o Is the benchmark for a vaccine too high given the effectiveness of LAAV regimen?
- To achieve success must reach all those disproportionately affected - How can PPP help to achieve this?
Defining immune health and its implications for ID & Cancer
WVIC - Plenary - Constellation A&B
- How do we define immune fitness / immune health – progress towards human immunome
- How are we studying this at a systems level? How do vaccines positively impact immune fitness?
- Defining tumor archetypes – what common immunological features contribute to better response rates
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
How can partnering with federal labs help your business?
Interactive Roundtables
How can we utilize mRNA technology to develop next generation therapeutics?
Interactive Roundtables
Ariel Weinberger, Chief Executive Officer, Autonomous Therapeutics
How to effectively tailor prevention and treatment strategies to pediatric populations?
Interactive Roundtables
The future of vaccine trial sites post-COVID
Interactive Roundtables
Exhibition & Partnering Break
Keynotes
- Lunch served in exhibition area
- One-to-one networking meetings, Poster Presentations
Chair’s opening remarks
WVIC - ID Vaccines - Constellation A
Chair’s opening remarks
WVIC - Immune Profiling & Technology - Constellation B
Chair’s opening remarks
WVIC - Cancer Immunotherapy - Britannia/Cambria
Chair’s opening remarks
WAC - HIV - Commodore A
Chair’s opening remarks
WAC - Emerging & Reemerging Diseases - Commodore B
Oral COVID-19 vaccine ph II trials
WVIC - ID Vaccines - Constellation A
Panel: Understanding the TME; what’s left to learn?
WVIC - Immune Profiling & Technology - Constellation B
- How can we apply proteomics to the TME – how is this informing multiple targets?
- Balancing power of profiling and proteomics – will proteomics ever be ready for plug and play in the clinic?
- Advances in imaging the TME
- Characterizing effective T cell responses in and that track to the TME
- Non-tumor components of the TME as a therapeutic strategy -stromal cells, myeloid cells, other tissue resident cells
Sanjay Khare, EVP, Head of Immuno-Oncology Research, Coherus BioSciences
Galinpepimut-S: Clinical development of a WT1-targeting multivalent heteroclitic epitope immunotherapeutic
WVIC - Cancer Immunotherapy - Britannia/Cambria
Visualizing vaccine-induced on- and off-target antibody responses to HIV Env using electron microscopy
WAC - HIV - Commodore A
The Centers for Research in Emerging Infectious Diseases (CREID) Network: Research Integrated Surveillance and Monitoring
WAC - Emerging & Reemerging Diseases - Commodore B
PTX-COVID19-B mRNA Vaccine: Phase 2 Immunobridging Study vs. Comirnaty® Topline Results
WVIC - ID Vaccines - Constellation A
Updates in the clinical development of therapeutic glioblastoma vaccine, VBI-1901
WVIC - Cancer Immunotherapy - Britannia/Cambria
Kick and kill approach to HIV treatment
WAC - HIV - Commodore A
Applying machine learning for antiviral drug discovery
WAC - Emerging & Reemerging Diseases - Commodore B
SARS-CoV-2 Vaccine design to broaden effector immune responses
WVIC - ID Vaccines - Constellation A
Progress of therapies to overcome suppression in the TME
WVIC - Immune Profiling & Technology - Constellation B
A new approach to therapeutic cancer vaccines
WVIC - Cancer Immunotherapy - Britannia/Cambria
Using nanocrystal prodrugs as ultra-long-acting chemical treatment for HIV
WAC - HIV - Commodore A
Dr Howard Gendelman, Co-founder, Exavir Therapeutics
Development of broad-spectrum protease inhibitors to combat emerging viral diseases
WAC - Emerging & Reemerging Diseases - Commodore B
A new vaccine platform for emerging virus threats such as SARS-2, HIV, and RSV
WVIC - ID Vaccines - Constellation A
FortiVac APC-targeted vaccine for powerful CD8+ T cell responses
WVIC - Cancer Immunotherapy - Britannia/Cambria
Glycoconjugate approaches for evoking antibodies to sugars on HIV-1
WAC - HIV - Commodore A
Fleximers - a strategic approach to broad spectrum antiviral therapeutics
WAC - Emerging & Reemerging Diseases - Commodore B
Preclinical evaluation of a low-dose universal SARS-CoV-2 mRNA vaccine
WVIC - ID Vaccines - Constellation A
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Vaccine trial storage and distribution challenges
WVIC - ID Vaccines - Constellation A
Mapping immune profiles to improve clinical outcomes in oncology
WVIC - Immune Profiling & Technology - Constellation B
Novel Checkpoint Inhibitor Combination Vaccines (PD-1, PD-L1, CTLA-4, TIGIT, LAG3)
WVIC - Cancer Immunotherapy - Britannia/Cambria
Confronting the access challenges for HIV prevention: a law and policy perspective
WAC - HIV - Commodore A
Tackling multiple Marburg virus strains with humanized mAbs
WAC - Emerging & Reemerging Diseases - Commodore B
Improving clinical trial recruitment
WVIC - ID Vaccines - Constellation A
A novel platform for early diagnosis & predicting responses to immune checkpoint inhibitor treatment
WVIC - Immune Profiling & Technology - Constellation B
Versamune t-cell activating platform for HPV related cancers
WVIC - Cancer Immunotherapy - Britannia/Cambria
Are long-acting ARTs the future of HIV prevention and treatment?
WAC - HIV - Commodore A
- How can we improve the half-life of long-acting ARTs?
- How can we enhance the uptake/usage of long-acting formulations?
- What are the implementation challenges for therapies?
- What are the key policy issues for these types of therapies?
- Why can long-acting injectable therapies be difficult to access in LMIC?
Dr Howard Gendelman, Co-founder, Exavir Therapeutics
A repurposing antiviral solution for the prevention and treatment of Dengue
WAC - Emerging & Reemerging Diseases - Commodore B
How Benchmark Research used an innovative real-time data capture tool to reduce protocol deviations by 40% on vaccine trials
WVIC - ID Vaccines - Constellation A
Eric Elander, Director Business Development, Clinical Research IO (CRIO)
How to moonshot clinical trial diversity
WVIC - ID Vaccines - Constellation A
Studies informing mechanisms of resistance in oncology
WVIC - Immune Profiling & Technology - Constellation B
7HP349, an integrin agonist to overcome resistance to immune checkpoint blockade
WVIC - Cancer Immunotherapy - Britannia/Cambria
Structural mapping of the humoral immune response to the Lassa virus glycoprotein
WAC - Emerging & Reemerging Diseases - Commodore B
Establishment of a high-throughput screening platform for antivirals: Zika Protease
WAC - Emerging & Reemerging Diseases - Commodore B
Evening Networking Drinks Reception, come to the beautiful hotel terrace (outside)
Evening Networking Drinks
Sponsored by Headlands Research
Create your personal agenda –check the favourite icon
Chair’s opening remarks: The Antiviral Program for Pandemics (APP) and key support mechanisms available
WAC - Plenary - Commodore A&B
Global Health Goals – can we get back on track?
WVIC - Plenary - Constellation A&B
- How has the pandemic affected the status of the epidemics of tuberculosis, malaria and neglected tropical diseases?
- Silver linings – new investments in immunization infrastructure – understanding of barriers and opportunities in promoting vaccination within communities and countries. How do we try to capitalize on some of the new pathways generated because of covid?
- How will malaria vaccines be implemented? How does this vaccine need to be promoted differently to previous vaccines? How to communicate value of vaccines in burdened communities. Integrated strategy required.
- TB vaccines how are we moving forward? Next steps for TB vaccines.
Panel: What is the future of COVID-19 therapeutics?
WAC - Plenary - Commodore A&B
- What are the key areas of focus for 2023 and onwards?
- What novel therapies are being investigated?
- Is there a particular part of the SARS-CoV-2 infection cycle being targeted?
- Is there a silver bullet out there and what would it look like?
- How to ensure therapeutic interventions are easily accessible?
- How will the current and future COVID-19 therapeutics be used in the case of a new outbreak?
Dr Meghan Pennini, Chief Therapeutics Officer, HCORE, HHS
Dr Jay Grobler, Associate Vice President Infectious Disease and Vaccines, Merck And Company
Challenges & opportunities in moving immuno-oncology drugs into earlier lines of therapy
WVIC - Plenary - Constellation A&B
- What are the challenges that need to be overcome before we can move immunotherapies into earlier stages?
- What is effect of moving earlier in moving into adjuvant/neoadjuvant space? The need to understand progression much earlier in disease.
- What are our current assumptions – what data do we need to pressure test them? How do we collect data? What data do we need?
Panel: Overcoming obstacles in developing therapeutics for neglected and emerging diseases
WAC - Plenary - Commodore A&B
- What are the challenges in designing effective clinical trials for these diseases?
- What role do platform trials play?
- What are the key regulatory issues?
- How would a collaborative nature between researchers and regulatory help with development?
- Why is funding an issue? What can be done to combat this issue?
- How to react most efficiently to unexpected disease surges (e.g Monkeypox outbreak)
Nathalie Strub-Wourgaft, COVID-19 Response & Pandemic Preparedness Director,, Drugs for Neglected Diseases initiative-DNDi
Dr Phil Gomez, Chief Executive Officer, SIGA Technologies, Inc.
Mara Kreishman-Deitrick, Deputy Commander, United States Army Medical Material Development Activity
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Chair’s opening remarks
WVIC - Immune Profiling & Technology - Constellation B
Chair’s opening remarks
WVIC - Cancer Immunotherapy - Britannia/Cambria
Chair’s opening remarks
WAC - COVID-19 - Commodore A
Chair’s opening remarks
WAC - Delivery & Technology - Commodore B
Panel: Research & development goals for influenza vaccines
WVIC - ID Vaccines - Constellation A
- What is the status of the influenza vaccine R&D landscape?
- What areas of R&D are we focusing on to improve influenza vaccines?
- Strategic goals for seasonal vs universal flu vaccines
- Recent milestones achieved and gaps to address
- What tools do we need to inform policy, and preparedness planning?
- Pivoting to new manufacturing platforms to ensure faster response – what are the challenges
Recent studies informing our understanding of SARS-CoV-2 Immunity
WVIC - Immune Profiling & Technology - Constellation B
PIONEER – development of patient specific cancer immunotherapies
WVIC - Cancer Immunotherapy - Britannia/Cambria
Pegylated interferon lambda—a single dose treatment for COVID
WAC - COVID-19 - Commodore A
Innovative antiviral drug discovery software – Case study COVID Moonshot
WAC - Delivery & Technology - Commodore B
A CRO harnessing a multi-faceted diagnostic approach to support a Moderna SARS-COV-2 Phase 3 vaccine trial
WVIC - Immune Profiling & Technology - Constellation B
Stem cell-based platforms for delivery and potentiation of oncolytic viruses
WVIC - Cancer Immunotherapy - Britannia/Cambria
Structure-based drug design against SARS-CoV-2 main protease using X-rays, neutrons and computation
WAC - COVID-19 - Commodore A
AI driven automated viral infectivity assay to expedite antiviral drug discovery
WAC - Delivery & Technology - Commodore B
SERA identifies antibody epitopes induced by Moderna vaccines and boosters
WVIC - Immune Profiling & Technology - Constellation B
Development of mosaic nanoparticle vaccines to elicit broadly protective antibody responses
WVIC - ID Vaccines - Constellation A
Rapid detection of neutralizing antibodies and resistant viruses that escape antibody recognition
WVIC - Immune Profiling & Technology - Constellation B
Individualized Neoantigen Immunotherapy in early stage and advanced solid tumors
WVIC - Cancer Immunotherapy - Britannia/Cambria
Development of fully human monoclonal antibodies against SARS-CoV2 using peripheral B-cells from COVID-19 survivors
WAC - COVID-19 - Commodore A
Pathological modeling and control system for optimizing antivirals for COVID-19 and beyond
WAC - Delivery & Technology - Commodore B
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Infectimmune platform for univerval flu vaccine development
WVIC - ID Vaccines - Constellation A
Siva Gandhapudi, Director, Immunology Operations, P.D.S. Biotechnology Corp
Development of custom assays to measure vaccine efficacy
WVIC - Immune Profiling & Technology - Constellation B
Personal dendritic cell vaccines for cancer and covid-19
WVIC - Cancer Immunotherapy - Britannia/Cambria
Showcase 1: Driven by personal experience: Discovery and development of broad-spectrum antiviral agents against respiratory track viruses
WAC - COVID-19 - Commodore A
Vaccine and Treatment Efficacy: viral disease, patient illness perception and implications for respiratory viral challenge studies
WAC - Delivery & Technology - Commodore B
Novel FluoroSpot assay to detect rare Memory B cells and their role in P.falciparum malaria
WVIC - Immune Profiling & Technology - Constellation B
Showcase 2: Zapnometinib: a broad-spectrum antiviral for Covid-19, Influenza and other viral diseases with pandemic potential
WAC - COVID-19 - Commodore A
LUNAR – Flu & Covid-19 Vaccines
WVIC - ID Vaccines - Constellation A
Sean Sullivan, Executive Director, Head of Technology Innovation, Arcturus Therapeutics
Pre-clinical evaluation of HIV envelope glycoprotein vaccine candidates towards the clinic
WVIC - Immune Profiling & Technology - Constellation B
CARG-2020, an oncolytic and immunotherapy self-amplifying mRNA vector for treatment of solid tumors, prevents tumor recurrence
WVIC - Cancer Immunotherapy - Britannia/Cambria
Showcase 3: Ensitrelvir, a novel 3C-like protease inhibitor for once daily oral treatment of mild-to-moderate COVID-19
WAC - COVID-19 - Commodore A
Targeted Protein Degradation–A novel approach to combat viral pathogens
WAC - Delivery & Technology - Commodore B
Dr Priscilla Yang, Professor, Stanford University School of Medicine (USA)
Showcase 4: Broad spectrum inhibitors against viral methyltransferases
WAC - COVID-19 - Commodore A
Codon-deoptimized live attenuated vaccines for respiratory pathogens
WVIC - ID Vaccines - Constellation A
Intensified, low-cost manufacturing of viral vectors and viral vaccines using HIP-Vax technology
WVIC - Immune Profiling & Technology - Constellation B
Showcase 5: Broadly acting cathepsins inhibitor against omicron and other variants of concern
WAC - COVID-19 - Commodore A
Inhaled Interferon-beta (SNG001) for the treatment of COVID-19 and other severe viral lung infections
WAC - Delivery & Technology - Commodore B
Phillip Monk, CSO, Synairgen Research Ltd
From sequence to manufacturable spike proteins for vaccine development
WVIC - Immune Profiling & Technology - Constellation B
Showcase 6: Mechanism based designed 3CL inhibitors. From HRV to Covid19
WAC - COVID-19 - Commodore A
Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Developing broad-spectrum influenza vaccines against pandemic threats
WVIC - ID Vaccines - Constellation A
Intranasal Immunization: Device and Formulation Promises and Challenges
WVIC - Immune Profiling & Technology - Constellation B
Developing oral tissue-targeted TLR7 agonists for cancer immunotherapy
WVIC - Cancer Immunotherapy - Britannia/Cambria
Treating COVID-19 in Pregnancy – The COVID-19 International Drug Pregnancy Registry (COVID-PR)
WAC - COVID-19 - Commodore A
A Pan-Coronavirus + Pan-Influenza Therapeutic: One Drug for Many Bugs to Address Future Pandemics
WAC - Delivery & Technology - Commodore B
Molecular and immunogenetic definitions of broadly conserved influenza vaccine epitopes
WVIC - ID Vaccines - Constellation A
How broadly neutralizing antibodies guide the design of pan-beta coronavirus vaccines
WVIC - Immune Profiling & Technology - Constellation B
Developing engineered IgM antibodies for cancer
WVIC - Cancer Immunotherapy - Britannia/Cambria
Pandemic Antiviral Discovery (PAD) initiative–Catalysing antiviral discovery and development
WAC - COVID-19 - Commodore A
Cellular Nanosponges as an Emerging Antiviral Technology
WAC - Delivery & Technology - Commodore B
End of conference sessions, please make your way to the entrance for coaches to our off-site networking drinks
Keynotes
Please make your way to the entrance for coaches to our off-site networking drinks at Stone Brewery
Coaches to Off-site Networking Drinks Reception - Stone Brewery
Evening Networking Drinks
Please make your way to the entrance for coaches to our off-site networking drinks at Stone Brewery
Create your personal agenda –check the favourite icon
Chair’s opening remarks
WVIC - Plenary - Constellation A&B
Chair’s opening remarks
WAC - Plenary - Commodore A&B
Accelerating innovation –leveraging partnerships and collaborations to advance solutions to ID & Cancer
WVIC - Plenary - Constellation A&B
- What are the advantages of partnering with big pharma, federal labs, accelerators, foundations and private investors?
- What are their programmatic interests of the players involved in getting technologies to market?
- What emerging technologies are those in charge of partnering and collaboration most excited about?
- How can you position yourself optimally to get your tech noticed?
Panel: Therapeutic approaches to pandemic preparedness
WAC - Plenary - Commodore A&B
- Prediction–Predicting the next viral threat and developing a drug with a specific target
- Broad-spectrum–Developing drugs that work broadly across many stains/viruses
- Platforms–Warp speed platforms to develop therapeutics once a threat appears
- What are the advantages and disadvantages of each approach?
Dr Peter Daszak, President, Ecohealth Alliance Inc.
BRUNCH - Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Chair’s opening remarks
WVIC - ID Vaccines - Constellation A
Chair’s opening remarks
WVIC - New Technology & Partnerships - Constellation B
Chair’s opening remarks
WAC - Respiratory Viruses - Commodore A
Chair’s opening remarks
WAC - Hepatitis - Commodore B
Progress towards GAS vaccines
WVIC - ID Vaccines - Constellation A
How can an Intellectual Property International Consortium (IPIC) benefit small biotechs?
WVIC - New Technology & Partnerships - Constellation B
Developing immune cell ligands as a treatment strategy for influenza
WAC - Respiratory Viruses - Commodore A
Imrul Shahriar, Scientist, Eradivir Therapeutics; Graduate Research Assistant & PhD Candidate, Purdue Unviersity
New and Emerging Strategies for the Treatment and Potential Cure of Hepatitis B Virus and Hepatitis D Virus Infections
WAC - Hepatitis - Commodore B
How are investors thinking about biopharma stocks?
WVIC - New Technology & Partnerships - Constellation B
Bacterial structural vaccinology and novel target delivery
WVIC - ID Vaccines - Constellation A
Showcase 1: Early development of Smallpox & Monkey Pox Vaccines
WVIC - New Technology & Partnerships - Constellation B
Novel broad-spectrum influenza A PB2 inhibitor: clinical update
WAC - Respiratory Viruses - Commodore A
Subviral particle clearance and transaminase flares – roles in functional cure
WAC - Hepatitis - Commodore B
A Combinatorial Live Attenuated Vaccine Strategy Against Pneumonia and Otitis Media
WVIC - ID Vaccines - Constellation A
B-Tech vector platform for development of next gen Pertussis and TB vaccines
WVIC - ID Vaccines - Constellation A
Showcase 2: A new class of RNA for pan-variant immunity
WVIC - New Technology & Partnerships - Constellation B
Ariel Weinberger, Chief Executive Officer, Autonomous Therapeutics
The role of influenza antivirals–How can we reduce morbidity and mortality at the individual and population level?
WAC - Respiratory Viruses - Commodore A
BRUNCH - Exhibition & Partnering Break
Keynotes
- Tea, Coffee and Refreshments served in the exhibition area
- One-to-one networking meetings, Poster Presentations
Vaxchora® (Cholera Vaccine, Live, Oral) – An Overview
WVIC - ID Vaccines - Constellation A
Showcase 3: Engineering a novel SARS-CoV2 B-cell epitope vaccine and investigation in transgenic K18-hACE2 mice
WVIC - New Technology & Partnerships - Constellation B
Development of CARG-201, a self-amplifying mRNA vector, for immunotherapy of chronic hepatitis B
WAC - Hepatitis - Commodore B
Neutralizing Staphylococcus aureus virulence for vaccination and immunotherapy
WVIC - ID Vaccines - Constellation A
Showcase 4: PLACCINE Nucleic Acid Vaccine Platform – Preclinical POC using a SARS-CoV-2 pDNA construct
WVIC - New Technology & Partnerships - Constellation B
Lonafarnib—first oral antiviral for Hepatitis D
WAC - Hepatitis - Commodore B
Joint Closing Keynote Plenary Session Opening Remarks
WVIC - Plenary - Constellation A&B
Keynote Presentation of the Upcoming Film: SHOT IN THE ARM
WVIC - Plenary - Constellation A&B
Please join us for a special sneak peek and a keynote discussion of SHOT IN THE ARM, the new documentary from Academy Award nominated director Scott Hamilton Kennedy. Through the lens of the COVID-19 pandemic, and the vantage point of top medical experts (featuring Paul Offit, Peter Hotez and Tony Fauci) and anti-vaccine activists (featuring Robert Kennedy, jr., Andrew Wakefield and Del Bigtree), the film explores how difficult it is for the public to make the best decisions in the face of overwhelming distrust and disinformation. As well as how empathy and understanding of reasons behind vaccine hesitancy are powerful tools to help restore confidence and faith in public health and the social contract to protect our communities.
last published: 01/Dec/22 17:25 GMT
Password must meet the following requirements:
- At least one letter
- At least one capital letter
- At least one number
- Be at least 6 characters
Rebecca Kurnat M.S., Head of Product,
Saponiqx
Executive with the ability to provide strategic leadership across all phases of drug development based upon 20 years’ experience managing large, technically complex, programs and product portfolios, with increasing influence from academia through private industry, in pursuit of Food and Drug...
Steven Reed, Chief Executive Officer,
HDT Bio Corp
Steve Reed is the co-founder, President, and CEO of HDT Bio, based in Seattle, USA. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College Research Professor of Pathobiology at the University of Washington. Dr. Reed received a PhD in Microbiology and...
Upendra Marathi, Chief Executive Officer,
7 Hills Pharma LLC
Upendra Marathi, PhD, MBA is the CEO and a co-founder of 7 Hills Pharma. He is an inventor of their first-in-concept technology and a significant investor in the company. He has led the development of three novel pain and cardiovascular drugs, including one recently approved by the FDA. He...
John Baldoni, Head of Science,
Saponiqx
Dr. John Baldoni has developed an expansive portfolio over 40+ years in the pharmaceutical industry. His previous positions include Senior Vice President of Drug Discovery, and Senior Vice President of Platform Technology and Science (PTS) at GSK Pharma R&D. His experience spans chemical entity ...
Harry Sutton, Post-doctoral Fellow, Center for Infectious Disease and Vaccine Research,,
La Jolla Institute for Allergy and Immunology
Harry Sutton is Post-doctoral Scholar in the Crotty lab at the La Jolla Institute for Immunology. He completed his PhD in 2021 at the John Curtin School of Medical Research in Canberra, Australia. His primary research interests have been studying how B cells respond to vaccine targets of infectious ...
Colin Havenar-Daughton, Director of Immunology,
Vir Biotechnology
Colin Havenar-Daughton is a Director of Immunology at Vir Biotechnology. He earned his PhD degree in Immunology from the University of Washington. Colin conducted postdoctoral studies in Shane Crotty’s laboratory at the La Jolla Institute, where he focused on the immunological underpinnings of...
Sha Ha, VP CMC,
IGM Infectious Diseases, Inc.
Sha Ha is the Vice President of CMC at IGM Biosciences. She oversees drug substance and drug product development as well as analytical development in the Doylestown PA site. Before joining IGM, Sha was the director of Vaccine Process Development and Commercialization at Merck. She managed Phase 3...
Shivshankar Sundaram, Director, Center for Bioengineering, Executive Director, Predictive Design of Biologics,
Lawrence Livermore National Laboratory
Shankar Sundaram currently serves as the Director for the Center for Bioengineering at the Lawrence Livermore National Laboratory. In this capacity, he leads the laboratory’s Bioengineering strategy and technology development activities that address critical challenges in health and biosecurity. He ...
Haoyang Li, Instructor, Center for Infectious Disease and Vaccine Research,
La Jolla Institute
Haoyang recieved his PhD in Pathogenic Organisms from Fudan University and works at La Jolla Institute.
Helen Dooley, Assistant Professor,
University of Maryland School of Medicine
Helen Dooley obtained her PhD at the University of Aberdeen, UK. After a post-doc at the University of Maryland, Baltimore, USA, she spent a few years working in the Global Biotherapeutics division of Wyeth, retaining this role with Pfizer post-takeover. She is now Assistant Professor at University ...
Dr Barbara Rath, Co-founder & Chair, Vaccine Safety Initiative; Chair, ISIRV Epi Group, Board Member, ISIRV & ESCMID/ESGREV,
Vaccine Safety Initiative
Barbara A. Rath, MD PhD is a board-certified pediatric consultant and infectious disease specialist with 20 years experience in clinical trials, public health and virology in the US, Latin America and Europe. Dr. Rath is honorary professor at the University of Nottingham School of...
Carl Dieffenbach, Director, Division of AIDS,
NIAID/NIH
Dr. Carl W. Dieffenbach is the Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Under his leadership, the Division supports a global research portfolio to advance biological knowledge of HIV/AIDS, its related...
Carl Dieffenbach, Director, Division of AIDS,
NIAID/NIH
Dr. Carl W. Dieffenbach is the Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Under his leadership, the Division supports a global research portfolio to advance biological knowledge of HIV/AIDS, its related...
Brett Leav, Head, Clinical Development, Public Health Vaccines,
Moderna
Brett Leav, MD is Head of Clinical Development for Public Health Vaccines at Moderna. He was responsible for overseeing the Moderna COVID-19 vaccine clinical program in adults and children and now leads development of other vaccines to prevent intractable public health challenges, including...
Jared Baeten, Vice President, HIV Clinical Development,
Gilead Sciences
Jared Baeten, MD, PhD is Vice President of Clinical Development at Gilead Sciences, leading the company's strategy for HIV Treatment, Prevention, and Cure.Jared has conducted extensive research over the past two decades focusing on the prevention of HIV globally, including clinical...
Max Lataillade, Vice President, Head of Global Research Strategy,
ViiV Healthcare
Max Lataillade VP Head of global Research Strategy, is responsible for global research and development strategy for the HIV pipeline at ViiV Healthcare, the only company 100% dedicated to HIV. He oversees end-to-end R&D activities for all novel HIV pipeline programs designed to address key...
Pervin Anklesaria, Deputy Director,
The Bill & Melinda Gates Foundation
Pervin Anklesaria leads the HIV vaccines and biologics prevention efforts for the foundation’s HIV team. She joined the foundation in 2011 as a consultant and in 2012 became a senior program officer working on the foundation’s HIV vaccine and biologics initiatives.
Pervin has held leadership roles ...
William Schief, Professor, Department Of Immunology And Microbiology,
The Scripps Research Institute
William Schief Dr. William Schief is a Professor in the Immunology and Microbial Science Department at The Scripps Research Institute in La Jolla, CA, Director for Vaccine Design at the International AIDS Vaccine Initiative (IAVI), and an Associate Member of the Ragon Institute of MGH, MIT and...
Ananda Goldrath, Tata Chancellor's Endowed Professor in Molecular Biology,
UCSD
Ananda Goldrath is a Tata Chancellor’s Professor in the Division of Biological Sciences and former chair of the Molecular Biology Section at the University of California, San Diego, where she started her lab in 2004.
Bali Pulendran, Professor, Department Of Pathology, Microbiology And Immunology,
Stanford University School of Medicine (USA)
Professor Bali Pulendran is the Violetta L. Horton Professor at the Stanford University School of Medicine, and a member of the Institute for Immunology, Transplantation and Infection, and the Departments of Pathology and Microbiology & Immunology at Stanford University. He is also an adjunct...
Mark Doherty, Senior Manager, Global Medical Affairs,
GSK
Current work involves training (both for internal staff and for external medical professionals) and speaking to external audiences on vaccine development and immunology. Also involved in drafting policy documents in the area of vaccine development, public health and immunodiagnosis.
Rafick-Pierre Sékaly, Professor and Vice-Chair of Translational Medicine,
Emory University - School of Medicine
Rafick-Pierre Sékaly, PhD, is Professor and serves as Vice-Chair of Translational Medicine in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine in Atlanta, Georgia. Dr. Sékaly is a Georgia Research Alliance Eminent Scholar. He is a member of the Cancer...
Michael Salgaller, Supervisor, Invention Development And Marketing Unit,
National Cancer Institute - NIH
Experienced biopharma and life sciences senior manager with strong and successful background in technology development, entrepreneurship, business development, strategic planning, clinical and medical affairs, R&D, and capital formation.
Michael Mowatt, Director, Technology Transfer And Intellectual Property Office,
National Institute of Health - NIAID
Since 2001 Dr. Mowatt has directed the technology transfer program at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). His team of fifty talented professionals includes scientists, attorneys, and former business persons who facilitate...
Dr Barbara Rath, Co-founder & Chair, Vaccine Safety Initiative; Chair, ISIRV Epi Group, Board Member, ISIRV & ESCMID/ESGREV,
Vaccine Safety Initiative
Barbara A. Rath, MD PhD is a board-certified pediatric consultant and infectious disease specialist with 20 years experience in clinical trials, public health and virology in the US, Latin America and Europe. Dr. Rath is honorary professor at the University of Nottingham School of...
William Smith, Chief Executive Officer,
Alliance for Multispecialty Research LLC
Dr. William Smith is the Founder, President, and Principal Investigator of VRG and NOCCR, the AMR centers in Knoxville, TN and New Orleans, LA. He is also one of the original founders of AMR. Dr. Smith is board certified in Internal Medicine, Critical Care Medicine, Nephrology and Cardiology. He...
Michael Mowatt, Director, Technology Transfer And Intellectual Property Office,
National Institute of Health - NIAID
Since 2001 Dr. Mowatt has directed the technology transfer program at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). His team of fifty talented professionals includes scientists, attorneys, and former business persons who facilitate...
Sonia Sharma, Assistant Professor and Director of the Division of Cell Biology,
La Jolla Institute
Sonia Sharma’s current research focuses on using unbiased, genome-scale approaches to unravel innate immunity, the body’s early immune response to microbial pathogens and neoplastic cells, which has also been implicated as a common causal factor in many inflammatory, allergic and autoimmune...
Lauren V Wood, Chief Medical Officer,
P.D.S. Biotechnology Corp
Dr. Wood joined PDS Biotechnology as Chief Medical Officer in February 2019. She has overall responsibility for clinical development of the novel, immune activating Verrsamuneâ platform product pipeline targeting HPV-related pre-cancer and advanced cancers as well as a broad spectrum of solid...
Dr Jocelyn Kim, Assistant Professor,
University of California, Los Angeles
Dr. Jocelyn Kim is currently an Assistant Professor at UCLA. She received her undergraduate and medical degrees from the University of Michigan, Ann Arbor. She completed her internal medicine residency at Johns Hopkins Hospital in Baltimore, Maryland. Her clinical infectious disease fellowship was...
Dr Barbara Rath, Co-founder & Chair, Vaccine Safety Initiative; Chair, ISIRV Epi Group, Board Member, ISIRV & ESCMID/ESGREV,
Vaccine Safety Initiative
Barbara A. Rath, MD PhD is a board-certified pediatric consultant and infectious disease specialist with 20 years experience in clinical trials, public health and virology in the US, Latin America and Europe. Dr. Rath is honorary professor at the University of Nottingham School of...
Sean Tucker, CSO,
Vaxart
Dr. Tucker completed his doctoral degree in Immunology at the University of Washington. Dr. Tucker is the Chief Scientific Officer and Vice President for Research at Vaxart, Inc, a company focused on mucosal vaccine delivery. He has published several papers in immunology and served as a grant...
Sonia Sharma, Assistant Professor and Director of the Division of Cell Biology,
La Jolla Institute
Sonia Sharma’s current research focuses on using unbiased, genome-scale approaches to unravel innate immunity, the body’s early immune response to microbial pathogens and neoplastic cells, which has also been implicated as a common causal factor in many inflammatory, allergic and autoimmune...
Nicholas Wilson, Vice President, Immunology & Stromal Biology TME TRC,
Bristol-Myers Squibb
Nicholas Wilson Ph.D is a Vice President at Bristol Myers Squibb. Nick leads the Immunology & Stromal Biology group at Bristol Myers Squibb’s Tumor Microenvironment Thematic Research Center (TME TRC) located in Redwood City, California. Nick has over 15 years of industry experience in oncology...
Sriram Venkataraman, CSO,
Foundery Innovations
Dr. Venkataraman Sriram (Sriram) is the Chief Scientific Officer at Foundery Innovations, Inc. Sriram has over 15 years of biopharmaceutical research experience developing biological and small molecule therapeutics against immunotherapy targets. Prior to starting Foundery, Sriram was at Pionyr...
Dragan Cicic, SVP of Clinical Development,
SELLAS Life Sciences Group AG
Dr. Cicic is Senior Vice President of Clinical Development. Dr. Cicic has 20 years of experience in the biopharmaceutical industry. Before joining SELLAS, he was a Senior Vice President, Clinical Lead, at Klus Pharma, a wholly owned U.S. subsidiary of Kelun, a major China-based multinational...
Gabriel Ozorowski, Sr. Laboratory Director,
The Scripps Research Institute
Dr. Gabriel Ozorowski has over 16 years of experience in protein structural biology, with a background in applying x-ray crystallography and cryo-electron microscopy (cryoEM) techniques to biomedical studies. He focuses on conformational states of HIV-1 Env and how they are affected by ligands...
Sara Woodson, Program Officer,
NIH/NIAID
Sara E. Woodson, PhD is virologist and expert in emerging and re-emerging viral diseases. She is currently a Team Lead & Program Officer for the Centers for Research in Emerging Infectious Diseases (CREID) Network program within the Translational Research Section of the Virology Branch in the...
Aleksandra Pastrak, CMO,
Providence Therapeutics Holdings, Inc.
Aleksandra Pastrak M.D Ph.D, Chief Medical Officer, is a medical professional with 23 years of experience in the life sciences industry, developing small molecules and biologic therapeutics for a diverse array of indications. Prior to joining Providence Therapeutics, Dr. Pastrak served as Medical...
David Anderson, Chief Scientific Officer,
VBI Vaccines
A dynamic and well-published immunologist with broad expertise in the areas of vaccine development, autoimmunity and tumor immunology, Dr. Anderson joined VBI full time in 2009 from Harvard Medical School, where he held a position as Assistant Professor. Dr. Anderson is an inventor of much of the...
Dr Jocelyn Kim, Assistant Professor,
University of California, Los Angeles
Dr. Jocelyn Kim is currently an Assistant Professor at UCLA. She received her undergraduate and medical degrees from the University of Michigan, Ann Arbor. She completed her internal medicine residency at Johns Hopkins Hospital in Baltimore, Maryland. Her clinical infectious disease fellowship was...
Ana Puhl, Associate Director,
Collaborations Pharmaceuticals
I am Senior Scientist at Collaborations Pharmaceuticals. I joined the company in 2018 and I am involved in drug discovery projects for rare genetic diseases, neglected diseases and antiviral research. At Collaborations, I am responsible for leading, managing and executing R&D projects in...
Mark Newman, CSO,
GeoVax, Inc.
Dr. Newman has more than 30 years’ experience in the biotechnology sector serving in senior management roles at GeoVax (Atlanta, GA), PaxVax (San Diego, CA), Pharmexa (Horsholm, Denmark), Epimmune (San Diego, CA), Vaxcel (Atlanta, GA), Apollon (Philadelphia, PA) and Cambridge Biotech (Boston, MA)...
Kamal Puri, CSO,
OncoResponse
Kamal Puri is the Chief Scientific Officer at OncoResponse Inc. He has over 25 years of R&D experience in immunology, oncology, and neurobiology. Kamal joined OncoResponse from Celgene, where he led efforts for immunology discovery. Prior to Celgene, he was at Gilead and contributed to the...
Stephen Albert Johnston, Co-Founder,
CALVIRI
Stephen Albert Johnston is the inventor of Calviri’s central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell (iCx), Inc. He is Director of the Arizona State University Biodesign Institute’s Center for Innovations in...
Bernd van Buuren, Chief Executive Officer,
Protinhi Therapeutics
Bernd co-founded Protinhi in 2013 and became CEO at the start of Protinhi’s operational activities in 2016. In that time he grew the company from 1 to 10 people and attracted a world leading scientific advisory board to Protinhi. Bernd has more than 25 years experience in Life Sciences R&D...
Bruce Lyday, CEO,
Coronavax LLC
Bruce Lyday has been a researcher in the fields of virology, immunology, and oncology for over 30 years. He developed a cancer immunotherapy that combines an oncolytic, immune stimulating virus, Dengue-1 #4AZ5, developed by the US Army as a vaccine, in combination with tumor peptide-pulsed...
Richard Kornbluth, President & Chief Scientific Officer,
Multimeric Biotherapeutics, Inc.
Dr. Richard Kornbluth is an immunologist, physician, and serial entrepreneur. Richard trained at Harvard (A.B.), New York Medical College (M.D.), Columbia University (Ph.D.), and the Scripps Research Institute (postdoc). He was a faculty member at Univ. Calif. San Diego where he worked on HIV...
Dr Ralph Pantophlet, Professor,
Simon Fraser University
Dr. Pantophlet completed his PhD at the University of Leiden, subsequent postdoctoral training at the Scripps Research Institute, and a one-year fellowship at Research Center Borstel. He began as a tenure track Assistant Professor in the Faculty of Health Sciences (FHS) at Simon Fraser University...
Dr Kathie Seley-Radtke, Professor Chemistry & Biochemistry,
University of Maryland Baltimore County
Dr. Kathie Seley-Radtke is a Professor in the Department of Chemistry & Biochemistry at the University of Maryland, Baltimore County. Her medicinal chemistry research focuses on targeting coronaviruses, filoviruses, flaviviruses among other infectious diseases, using her novel “fleximer”...
Renhuan Xu, Chief Executive Officer,
ARV Technologies
ARV Technologies is a start-up biotechnology company focused on developing innovative vaccines to address critical unmet medical needs in areas such as infectious diseases and oncology.
Kim Meinen, Senior Business Development Director,
Marken
Kimberly Meinen is the U.S. West Coast Senior Director of Business Development - Team Lead for Marken, a UPS Company. Kimberly currently has over 25 years of combined experience in the Pharmaceutical/Life Science/Medical Services Industries with strong experience in temperature sensitive supply...
Ramji Srinivasan, Chief Executive Officer,
Teiko Bio Inc.
Ramji is cofounder and CEO of teiko.bio. Teiko’s mission is to make immune profiling a reality for clinical trials, and eventually for patients. They are making that mission happen by performing deep immune characterization using single-cell mass cytometry. Their team includes 12 PhD-trained...
Pravin Kaumaya, Professor and Director Vaccine Research,
The Ohio State University Werner Medical Center
Kaumaya is Professor of Medicine in Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer, viral diseases as well as...
Richard Hughes, Partner, Epstein, Becker & Green, Professorial Lecturer in Law,,
The George Washington University Law School
Richard Hughes IV, J.D., M.P.H. is a Partner at the Washington, D.C. health care law firm, Epstein, Becker & Green and a Professorial Lecturer in Law at the The George Washington University Law School. His practice, teaching and thought leadership focus on access to preventive health...
M Javad Aman, President and Chief Scientific Officer,
Integrated BioTherapeutics
Javad Aman has been the President and Chief Scientific Officer (CSO) of Integrated BioTherapeutics, Inc. (IBT), a US biotechnology company focused on the discovery of vaccines and immunotherapeutics for emerging infectious diseases. Since 2007, he has led a group of 40 people working on several...
William Smith, Chief Executive Officer,
Alliance for Multispecialty Research LLC
Dr. William Smith is the Founder, President, and Principal Investigator of VRG and NOCCR, the AMR centers in Knoxville, TN and New Orleans, LA. He is also one of the original founders of AMR. Dr. Smith is board certified in Internal Medicine, Critical Care Medicine, Nephrology and Cardiology. He...
Stephen Albert Johnston, Co-Founder,
CALVIRI
Stephen Albert Johnston is the inventor of Calviri’s central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell (iCx), Inc. He is Director of the Arizona State University Biodesign Institute’s Center for Innovations in...
Lauren V Wood, Chief Medical Officer,
P.D.S. Biotechnology Corp
Dr. Wood joined PDS Biotechnology as Chief Medical Officer in February 2019. She has overall responsibility for clinical development of the novel, immune activating Verrsamuneâ platform product pipeline targeting HPV-related pre-cancer and advanced cancers as well as a broad spectrum of solid...
Dr Douglas Richman, Director, Center for Aids Research,
University of California San Diego
Dr. Richman conducted research on influenza virus, herpesviruses and hemorrhagic fever viruses before focusing on HIV in the 1980s. HIV drug resistance was originally recognized in his laboratory. His lab also identified the latent HIV reservoir as the obstacle to cure with antiretroviral...
Max Lataillade, Vice President, Head of Global Research Strategy,
ViiV Healthcare
Max Lataillade VP Head of global Research Strategy, is responsible for global research and development strategy for the HIV pipeline at ViiV Healthcare, the only company 100% dedicated to HIV. He oversees end-to-end R&D activities for all novel HIV pipeline programs designed to address key...
Paul Domanico, Senior Director of Global Health Sciences,,
Clinton Health Access Initiative (CHAI)
Paul L. Domanico joined CHAI in 2012 as the Senior Director of Global Health Sciences at CHAI. His department partners with industry, academia, and other global health organizations to advance adult and pediatric care, and support CHAI's mission to transform global health. Paul founded...
Ethel Weld, Assistant Professor of Medicine,
The Johns Hopkins University School of Medicine
Dr. Ethel D. Weld, MD, PhD is an assistant professor of medicine, pharmacology, and molecular sciences at the Johns Hopkins University School of Medicine. She earned her medical degree from the University of Chicago and her PhD in Clinical Investigation from the Johns Hopkins Bloomberg School of...
Jared Baeten, Vice President, HIV Clinical Development,
Gilead Sciences
Jared Baeten, MD, PhD is Vice President of Clinical Development at Gilead Sciences, leading the company's strategy for HIV Treatment, Prevention, and Cure.Jared has conducted extensive research over the past two decades focusing on the prevention of HIV globally, including clinical...
David Foster, Chief Executive Officer,
Island Pharmaceuticals
Dr. David Foster brings more than 20 years of experience working with early stage pharmaceutical and biotechnology companies developing a variety of therapeutics from biologics to small molecules. He has represented pharmaceutical, biotherapeutic and diagnostic companies, while in private legal...
Cynthia Dukes, CBO,
Benchmark Research
Cynthia “Cindy” Dukes, PA, MT, is Chief Business Officer to Benchmark Research, a 9 site multitherapeutic clinical research network that was founded 25 years ago with a core focus on vaccine studies. Cindy is a world-recognized professional in the vaccine industry. She has over 40 years of...
Michael Caldwell, Assoc VP Vaccine Research & Education,
Meharry Medical College
Dr. Caldwell is the Associate Vice President, Vaccine Research & Education at Meharry Medical College in Nashville TN. He leads the emerging partnership between Meharry and Clinical Research Associates of Nashville and is a devoted clinician and teacher. Dr. Caldwell serves as an investigator...
Chardae Foster, Medical Student; Lead, Physician Education & Training Program,
Meharry Medical College
Chardae Foster is a medical student at Meharry Medical College in Nashville, TN. She earned her BS at the University of Tennessee, Knoxville where she majored in Neuroscience in pursuit of a medical career in Neurology. Her passion to become a Neurologist was sparked by her brother who has Epilepsy ...
Nicholas Wilson, Vice President, Immunology & Stromal Biology TME TRC,
Bristol-Myers Squibb
Nicholas Wilson Ph.D is a Vice President at Bristol Myers Squibb. Nick leads the Immunology & Stromal Biology group at Bristol Myers Squibb’s Tumor Microenvironment Thematic Research Center (TME TRC) located in Redwood City, California. Nick has over 15 years of industry experience in oncology...
Upendra Marathi, Chief Executive Officer,
7 Hills Pharma LLC
Upendra Marathi, PhD, MBA is the CEO and a co-founder of 7 Hills Pharma. He is an inventor of their first-in-concept technology and a significant investor in the company. He has led the development of three novel pain and cardiovascular drugs, including one recently approved by the FDA. He...
Philip Brouwer, Postdoctoral fellow,
Scripps Research
After obtaining his Masters degree in Pharmaceutical Sciences, Philip pursued his research interest as a graduate student at the Amsterdam University Medical Center. Under the mentorship of Prof. Rogier Sanders, as well as Dr. Neil King at the University of Washington, he worked on the development...
Adam Yasgar, Staff Scientist, Biology,
National Center for Advancing Translational Sciences (NCATS)
Adam S. Yasgar received a B.Sc. in chemistry at the George Washington University in 2001. As an undergraduate, he discovered his scientific passion for analytical chemistry through his work using high-performance liquid chromatography/mass spectrometry to separate and identify illegal components in ...
Carl Dieffenbach, Director, Division of AIDS,
NIAID/NIH
Dr. Carl W. Dieffenbach is the Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Under his leadership, the Division supports a global research portfolio to advance biological knowledge of HIV/AIDS, its related...
Steven Reed, Chief Executive Officer,
HDT Bio Corp
Steve Reed is the co-founder, President, and CEO of HDT Bio, based in Seattle, USA. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College Research Professor of Pathobiology at the University of Washington. Dr. Reed received a PhD in Microbiology and...
Yannick Vanloubbeeck, Head of Immunology,
GSK
Yannick Vanloubbeeck (DVM, PhD) is Head of Immunology at GSK Vaccines R&D, based in Belgium. He has joined GSK Vaccines in 2006 to lead the preclinical development of vaccine candidates against diseases of the developing world, including malaria & tuberculosis. In his current role he is...
Ashley Birkett, Global Head, Malaria Vaccines and Biologics,
PATH
Ashley Birkett is the Global Head of Malaria within PATH’s Center for Vaccine Innovation and Access (CVIA) and serves on the CVIA Leadership Team. CVIA brings together expertise across every stage of vaccine research, development, and introduction to make vaccines globally available to...
Alison Kraigsley, Program Officer, TB Vaccines,
The Bill & Melinda Gates Foundation
Alison Kraigsley is the TB Vaccines Program Officer at the Bill and Melinda Gates Foundation and is responsible for developing and managing a portfolio of research investments to address scientific gaps and support the development of a robust TB vaccine pipeline. Alison has a broad background in...
Carl Dieffenbach, Director, Division of AIDS,
NIAID/NIH
Dr. Carl W. Dieffenbach is the Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Under his leadership, the Division supports a global research portfolio to advance biological knowledge of HIV/AIDS, its related...
Dr Robert Jordan, Senior Program Officer,
Bill & Melinda Gates Foundation
Robert Jordan is a Senior Program Officer at the Bill and Melinda Gates Foundation. Prior to joining the BMGF, Robert was Vice President of Research and Development at Meissa Vaccines developing live attenuated virus vaccines for RSV and SARS-CoV-2 as well as other respiratory virus...
Dr Kimberly Armstrong, Chief of the Therapeutics Branch in the Influenza and Emerging Infectious Diseases Division,
BARDA
Kimberly Armstrong, Ph.D., MT (ASCP) is the Chief of the Therapeutics Branch in the Influenza and Emerging Infectious Diseases Division at the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the...
Nicholas Wilson, Vice President, Immunology & Stromal Biology TME TRC,
Bristol-Myers Squibb
Nicholas Wilson Ph.D is a Vice President at Bristol Myers Squibb. Nick leads the Immunology & Stromal Biology group at Bristol Myers Squibb’s Tumor Microenvironment Thematic Research Center (TME TRC) located in Redwood City, California. Nick has over 15 years of industry experience in oncology...
Scot Ebbinghaus, Vice President and Therapeutic Area Head for Late-Stage Oncology Clinical Development,
Merck
Dr. Scot Ebbinghaus joined Merck Research Labs Late Stage Oncology Development in 2007. He is currently Vice President and Therapeutic Area Head for Late Stage Oncology Development with responsibilities for overseeing the Keytruda (pembrolizumab) development program and other late stage assets in...
Ezra Cohen, Associate Director Of Moores Cancer Center,
U.C. San Diego Moores Cancer Center
Ezra Cohen, MD, is Chief of the Division of Hematology-Oncology, and Co-Director of the San Diego Center for Precision Immunotherapy. A physicianscientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to...
John Redd, CMO,
The Medical Countermeasures Coalition
Dr. John Redd is an internist and medical epidemiologist whoserved as the Chief Medical Officer (CMO) of the Office of theAssistant Secretary for Preparedness and Response (ASPR) atHealth and Human Services Headquarters in Washington, DCuntil he left government service in January 2022.Dr. Redd...
Annie Elong Ngono, Instructor, Center for Infectious Disease and Vaccine Research,
La Jolla Institute for Allergy and Immunology
Dr. Annie Elong Ngono is Research Instructor in the Center for Infectious Disease and Vaccine Research at the La Jolla Institute for Immunology (LJI). She received her Ph.D. in Immunology working on the role of autoreactive T and B cells in periphery using blood samples from patients with multiple...
Matthew G. Clark, Joint Project Manager, CBRN Medical,
JPEO-CBRND
Colonel Matthew G. Clark is the Joint Project Manager for Chemical, Biological,Radiological, and Nuclear Medical (JPM CBRN Medical). He is responsible for leading themedical portfolio for the Joint Program Executive Office for Chemical, Biological,Radiological and Nuclear Defense (JPEO-CBRND).COL...
Robert Dillman, Chief Medical Officer,
AIVITA Biomedical, Inc.
Dr. Robert O. Dillman, M.D., is Chief Medical Officer of AIVITA Biomedical. Previously, Dr. Dillman served as Vice President of Oncology at Caladrius Biosciences, Inc. (formerly Neostem, Inc.), a leading development and manufacturing partner to the cell therapy industry. From May 2014 to January...
Jeffrey Glenn, Professor of Medicine and of Microbiology & Immunology,
Stanford University
Jeffrey Glenn, M.D., Ph.D. is a Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He also heads a research laboratory focused...
Dr Abhishek Dutta, Assistant Professor,
University of Connecticut
Dr. Dutta is a Professor and Researcher with sustained international recognition who has risen to the top of his field of endeavor, that being in cybernetics and systems medicine. Dr. Dutta joined the University of Connecticut as an Assistant Professor, a tenure-track position, in August 2016 and...
Jacob Glanville, Chief Executive Officer,
Centivax
Jacob Glanville is an serial entrepreneur, and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the...
Sybil Tasker, CMO,
Codagenix Inc.
Dr. Tasker is an experienced infectious disease clinician and fellow of the American College of Physicians and the Infectious Diseases Society of America. Prior to joining Codagenix, she served as CMO of Altimmune, where she led the development and clinical testing of influenza and anthrax...
Alison Kraigsley, Program Officer, TB Vaccines,
The Bill & Melinda Gates Foundation
Alison Kraigsley is the TB Vaccines Program Officer at the Bill and Melinda Gates Foundation and is responsible for developing and managing a portfolio of research investments to address scientific gaps and support the development of a robust TB vaccine pipeline. Alison has a broad background in...
Kristin DeBord, Acting Deputy Director, Office of Strategy, Policy, Planning & Requirements,
Department of Health and Human Services
Dr. DeBord is the Acting Deputy Assistant Secretary for the Office of Strategy, Policy, Planning, and Requirements (SPPR) within the Administration for Strategic Preparedness and Response (ASPR). She provides leadership and oversight to the office, ensuring ASPR’s operational preparedness and...
Daniela Weiskopf, Instructor, Division Of Vaccine Discovery,
La Jolla Institute for Allergy and Immunology
Dr Daniela Weiskopf has devoted her career to understanding the T cell response to viral pathogens relevant to human health and disease. In 2009 she received her PhD in Microbiology and Immunology from Innsbruck Medical University, Austria, where she performed research analyzing post-translational...
Erik Heegaard, CMO,
Evaxion Biotech A/S
Erik Heegaard is a medical specialist, PhD, DMSc, and works as Chief Medical Officer at Evaxion. He is responsible for strategic development and tactical implementation of the clinical studies for Evaxion’s research programs. This includes providing direct medical/physician oversight for phase I/II ...
Jeffrey Glenn, Professor of Medicine and of Microbiology & Immunology,
Stanford University
Jeffrey Glenn, M.D., Ph.D. is a Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He also heads a research laboratory focused...
Quillon Simpson, Business Development Scientist,
Collaborative Drug Discovery Inc
Dr. Quillon Simpson works at Collaborative Drug Discovery (CDD), a hosted informatics platform that helps manage, analyze, and present data generated by biotech companies, CROs, academic labs, research hospitals, agrochemical and consumer goods companies. Quillon utilizes his experience in organic...
Dr Manisha Diaz, Associate Director, Research and Development,
Eurofins Viracor BioPharma
Dr. Diaz is the Associate Director, Research and Development, Eurofins Viracor BioPharma. She has over 6 years of experience in the pharmaceutical CRO industry. Her wide range of experience includes developing Immunoassays and viral diagnostic assays to support clinical trials. She has interest and ...
Boris Minev, President, Medical & Scientific Affairs,
Calidi Biotherapeutics
Dr. Minev is a highly accomplished physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development, having worked closely on the...
Dr Andrey Kovalevsky, Senior R&D Scientist,
Oak Ridge National Laboratory (ORNL)
Dr. Andrey Kovalevsky is a structural biologist, biochemist and a Senior R&D Scientist at the Oak Ridge National Laboratory. Dr. Kovalevsky studied organic chemistry and chemical crystallography at Kharkiv State University, Kharkiv, Ukraine, receiving M.Sc. degree with Honors. He received his...
Dr Ilya Goldberg, CSO,
ViQi, Inc
Dr. Ilya Goldberg has spent the majority of his career at the intersection of biology and imaging, and played a leading role in the development of image informatics and machine learning for bio-medical imaging since the emergence of these fields in the late '90s. At ViQi, Ilya leads development ...
John Shon, CTO,
Serimmune
John Shon is the Chief Technology Officer of Serimmune where he leads the development of informatics software and algorithms for the company's platforms. Dr. Shon was previously Vice President of Bioinformatics and Data Sciences at Illumina and has over a decade of experience in leadership...
Bethany Girard, Associate Director, Clinical Biomarkers,
Moderna
Bethany (Biron) Girard is the Associate Director – Clinical Biomarkers, Infectious Disease at Moderna Inc. and has been with the company since Oct 2020. In this role she serves as a scientific leader and point of contact for clinical teams in the Infectious Disease (ID) space, driving pivotal...
Alexander Cohen, Post-Doctoral Scholar, Division of Biology and Biological Engineering,,
California Institute of Technology
Dr. Alexander Cohen is a postdoctoral scholar in the Bjorkman lab at Caltech which is also where he received his PhD in Biochemistry and Molecular Biophysics (2021). His graduate and postdoctoral work have focused mainly on the development of a mosaic nanoparticle vaccination strategy for SARS-like ...
Naveen Suryadevara, Senior Staff Scientist,
Vanderbilt Vaccine Center
Dr. Suryadevara is a senior staff scientist in the laboratory of Dr. James E. Crowe, Jr. at Vanderbilt vaccine centre and is involved in developing methods pertaining to rapid identification of therapeutic antibodies against viral infections (DARPA’s Pandemic Protection Platform program). He served ...
Christine Palmer, Senior Director, Immunology,,
Gritstone bio
Dr. Palmer received her undergraduate degree in Biological Sciences from the University of Oxford, and her PhD in Immunology from Imperial College London. Following two postdoctoral fellowships at University College London and Harvard Medical School, Dr. Palmer joined the Ragon Institute of...
Dr Seth Lederman, Co-Founder, Chief Executive Officer & Chairman,
Tonix Pharmaceuticals
Seth Lederman is CEO of Tonix Pharmaceuticals. Prior to Tonix, and his career in Biotech, Dr. Lederman served as tenured Associate Professor at Columbia University and directed basic science research in molecular immunology, infectious diseases and the development of therapeutics for autoimmune...
Dr Abhishek Dutta, Assistant Professor,
University of Connecticut
Dr. Dutta is a Professor and Researcher with sustained international recognition who has risen to the top of his field of endeavor, that being in cybernetics and systems medicine. Dr. Dutta joined the University of Connecticut as an Assistant Professor, a tenure-track position, in August 2016 and...
Jennifer DeMarco, Project Leader, Custom Assay Design and Development,
Microbiologics
Jennifer DeMarco obtained her Master’s of Science at the University of Virginia, with an emphasis in immunology and infectious disease and a specialty in vaccine and therapeutic development. During the SARS-CoV-2 pandemic, her work was at the front of the field with assay and model development for ...
Dr Pratima Rawat, Virology Scientist,
Microbiologics
Obtaining her PhD in Biotechnology from the University of Pune, Pratima Rawat is a research scientist with over 12 years of multidisciplinary experience in preclinical and clinical research. She has experience in a variety of fields such as infectious disease biology, virology, HIV biology, and...
Robert Dillman, Chief Medical Officer,
AIVITA Biomedical, Inc.
Dr. Robert O. Dillman, M.D., is Chief Medical Officer of AIVITA Biomedical. Previously, Dr. Dillman served as Vice President of Oncology at Caladrius Biosciences, Inc. (formerly Neostem, Inc.), a leading development and manufacturing partner to the cell therapy industry. From May 2014 to January...
Dr Xicheng Sun, Vice President, Chemistry & Manufacturing,
Crestone, Inc.
Xicheng Sun, Ph.D. Vice President, Chemistry & Manufacturing at Crestone In. Prior to his current appointment, Dr Sun was an executive director of chemistry and CFTR modulator team leader at N30 Pharmaceuticals, overseeing internal and external activities from medicinal chemistry, chemical...
Alexander Mann, Senior Director, Clinical Sciences,
hVIVO
Alex Mann has a specific interest in the use of human challenge models to answer key questions around host responses to infection as well as efficacy of treatments and vaccines. Over the last 23 years at hVIVO (formally Retroscreen Virology Ltd.) he has led, managed, designed, and analysed an array ...
Peter Jahnmatz, Research And Development,
Mabtech
Dr. Peter Jahnmatz is an Immunologist with a PhD in immunology and infectious diseases from the Karolinska Institute in Sweden. He has worked extensively with cell-based immunoassay optimization and antibody development.
Nigel Horscroft, Chief Scientific Officer,
Atriva Therapeutics
Nigel Horscroft D.Phil. is Chief Scientific Officer and Executive Vice President for Preclinical Research at Atriva Therapeutics, a German biopharmaceutical company developing antiviral therapies. Dr. Horscroft holds a D.Phil. in Biochemistry from Oxford University where he studied Bluetongue Virus ...
Richard Wyatt, Professor, Department of Immunology and Microbiology,
The Scripps Research Institute
Richard T Wyatt, Ph.D., received his Doctorate in Immunology from Tufts University School of Graduate Biomedical Sciences in Boston, MA and did his postdoctoral training at the Harvard School of Medicine. Currently, Dr. Wyatt is a tenured Professor in the Department of Immunology and Microbiology...
Bijan Almassian, President and Chief Executive Officer,
CaroGen Corporation
Dr. Bijan Almassian is a co-founder, President and CEO of CaroGen Corporation. Prior to CaroGen, Dr. Almassian served as President and CEO of ExSAR Corp, COO of Panacea Pharmaceuticals, and Vice President of Drug Development at Vion Pharmaceuticals. Dr. Almassian holds a MS and PhD from...
Dr Takeki Uehara, Corporate Officer, Senior Vice President, Drug Development and Regulatory Science Division,
Shionogi & Co., Ltd.
Dr. Takeki Uehara received his DVM degree at the Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Japan, in 2002. After his graduation, he joined Shionogi & Co., Ltd. as a research scientist. In 2008 he received his PhD degree of...
Hongmin Li, Professor,
The University of Arizona
Dr. Hongmin Li is a Professor in the Department of Pharmacology and Toxicology and R. Ken and Donna Coit Endowed Chair in Drug Discovery at College of Pharmacy, the University of Arizona, Tucson AZ, USA. He received bachelor’s degree from Beijing University in 1990. Dr. Li graduated with PhD degree ...
Sybil Tasker, CMO,
Codagenix Inc.
Dr. Tasker is an experienced infectious disease clinician and fellow of the American College of Physicians and the Infectious Diseases Society of America. Prior to joining Codagenix, she served as CMO of Altimmune, where she led the development and clinical testing of influenza and anthrax...
Danielle Horneman, Project Manager, Bioprocess Scientist,
Batavia Biosciences
Danielle Horneman, PhD., works as a technical lead at Batavia Biosciences, where she provides scientific input and writes proposals for viral vector and viral vaccine process development and manufacturing projects.Danielle has a profound background in process development and production of...
Dr Felix Frueh, CSO and Co-Founder,
Selva Therapeutics, Inc.
Dr. Frueh was previously CSO at Human Longevity, Inc. He was the President of the Medco Research Institute and the first Associate Director for Genomics at FDA. In addition, he held executive positions in multiple biotechnology companies and serves on the Boards of several biotechnology...
Joshua Armitano, Program Officer,
ExcellGene SA
After obtaining a PhD in Microbiology at the University of Aix-Marseille and an EMBA in Healthcare Management at the University of Lausanne, Joshua Armitano joined ExcellGene in 2020 to manage several cell line development program including a Covid antigen development project supported by CEPI.
Gerald Commissiong, Chief Executive Officer,
Todos Medical Ltd.
Mr. Commissiong serves as Chief Executive Officer and a member of the Board of Directors of Todos Medical. He has over ten years of experience in therapeutic and diagnostic development, including all aspects of product licensing, research collaborations, and go-to-market strategies. He is the...
Jacob Glanville, Chief Executive Officer,
Centivax
Jacob Glanville is an serial entrepreneur, and computational immuno-engineer. He built and sold his first company Distributed Bio from founding in March of 2012 to a 104M dollar sale to Charles River Laboratories in December of 2020. During that period, he developed the core business model, the...
Nektaria Karavas, Business Development Director,
Aptar Pharma
Nektaria Karavas is the Global Director of Business Development for Nasal Vaccines, Antivirals and Immuno-stimulants at Aptar Pharma. Ms. Karavas joined Aptar Pharma in 2004 and has held various commercial roles executing long-term strategy within key customer and global accounts in North America...
Julie Suman, Vice President, Scientific Affairs,
Next Breath, an Aptar Pharma Company
Dr. Julie D. Suman is the Vice President of Scientific Affairs for Aptar Pharma. She manages strategic scientific planning and Aptar’s Scientific Advisory Board. Dr. Suman is also the co-founder of Next Breath, now an Aptar Pharma company. She holds a B.S. in Pharmacy from Duquesne University...
Andrew Miller, VP Immunology & Operations,
Apros Therapeutics
Andrew T. Miller, Ph.D. is the Vice President of Immunology and Operations, and co-founder of Apros Therapeutics, a clinical stage biotech focused on tissue-targeted TLR7 agonists for cancer immunotherapy, infectious disease, and vaccine adjuvants. Andrew has a strong track record of leading small...
Dr Diego Wyszynski, Chief Executive Officer,
Pregistry
Dr. Wyszynski’s main area of expertise is the assessment of drug and vaccine safety from observational data, with a special emphasis in the analysis of patterns of use and safety of drugs and vaccines during pregnancy. He received his medical degree from the University of Buenos Aires and Master...
Joshua McClure, Chief Executive Officer & Chairman,
Maxwell Biosciences
Joshua is an engineer with over 20 years of experience as a CEO. He is a multi-patent inventor, including anti-viral applications of Maxwell's platform technology. His background includes leading engineering teams, as well as military and commercial intelligence. He is a pioneer in the field of ...
Andrew Ward, Professor,
Scripps Research
Andrew Ward obtained a B.S. in Biology from Duke University in 2001. Upon graduation he moved to The Scripps Research Institute where he obtained his Ph.D. with Ronald Milligan, Ph.D. in cryoEM (2008) and conducted his postdoctoral work in structural biology and biophysics of membrane proteins with ...
Raiees Andrabi, Institute Investigator,
Scripps Reseach, La Jolla, CA
Raiees Andrabi is an Institute Investigator in the Department of Immunology and Microbiology at The Scripps Research Institute. Raiees Andrabi earned his PhD degree from the All India Institute of Medical Sciences in Biochemistry and performed his postdoctoral work in Dennis Burton’s laboratory at...
Liqin Liu, Head T-Cell Engager Projects, Immuno-Oncology Research Group,
IgM. Biosciences Inc
Liqin Liu currently is a Sr Director, head of T-cell engager programs at IGM Biosciences. In this role she oversees all T-cell engager research projects and serves as a scientific leader and expertise for T-cell engager portfolio/strategy development. Before joining IGM Biosciences, Liqin worked...
Dr Robert Jordan, Senior Program Officer,
Bill & Melinda Gates Foundation
Robert Jordan is a Senior Program Officer at the Bill and Melinda Gates Foundation. Prior to joining the BMGF, Robert was Vice President of Research and Development at Meissa Vaccines developing live attenuated virus vaccines for RSV and SARS-CoV-2 as well as other respiratory virus...
Dr Liangfang Zhang, Professor of Nanoengineering,
University of California San Diego
Dr. Liangfang Zhang is Joan and Irwin Jacobs Chancellor Professor of Nanoengineering and Bioengineering and Director of Chemical Engineering Program at the University of California San Diego. Dr. Zhang received his B.E. and M.S. degrees in Chemical Engineering from Tsinghua University, and his...
John Redd, CMO,
The Medical Countermeasures Coalition
Dr. John Redd is an internist and medical epidemiologist whoserved as the Chief Medical Officer (CMO) of the Office of theAssistant Secretary for Preparedness and Response (ASPR) atHealth and Human Services Headquarters in Washington, DCuntil he left government service in January 2022.Dr. Redd...
Taylor Sexton, Executive Director, Medical Countermeasures Coalition,
Todd Strategy Group
Taylor joined Todd Strategy Group in 2021 after serving as a Senior Advisor to the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. He served in this role through two administrations and the COVID-19 pandemic. He also maintained his...
Michael Salgaller, Supervisor, Invention Development And Marketing Unit,
National Cancer Institute - NIH
Experienced biopharma and life sciences senior manager with strong and successful background in technology development, entrepreneurship, business development, strategic planning, clinical and medical affairs, R&D, and capital formation.
Michael Mowatt, Director, Technology Transfer And Intellectual Property Office,
National Institute of Health - NIAID
Since 2001 Dr. Mowatt has directed the technology transfer program at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). His team of fifty talented professionals includes scientists, attorneys, and former business persons who facilitate...
Alex Szidon, Chief Business Officer,
Resilience
As Chief Business Officer, Alex Szidon is focused on strategic transactions that will help embed Resilience into the future of next-generation preventative, regenerative and curative therapies and vaccines. In this capacity, Alex and his team support and lead risk-sharing arrangements, equity...
Dr Michael Eichberg, Strategic Alliances Director,
Merck
Dr. Eichberg is Director of Strategic Alliances at Merck Research Laboratories, where he oversees collaborations in multiple therapeutic areas and with a variety of partners, including biopharmaceuticals, academic researchers, NGOs, and government agencies. In this role, Dr. Eichberg is involved...
Lesley Stolz, Regional Vice President, Early Innovation Partnering,
Johnson & Johnson Innovation
Lesley is Regional Vice President, Early Innovation Partnering at Johnson & Johnson Innovation, California. In this role, she leads identification, incubation, due diligence, negotiation, execution and on-boarding for high-impact partnerships and collaborations in external innovation. Lesley...
Jaione Maiz, Principal,
Anzu Partners
Dr. Jaione Maiz is a Principal at Anzu Partners with a focus on investing at the intersections of life science and innovative technology. She also supports portfolio companies in business development, strategy, and product development. Prior to Anzu, Jaione was a Director of Business Development at ...
Taylor Sexton, Executive Director, Medical Countermeasures Coalition,
Todd Strategy Group
Taylor joined Todd Strategy Group in 2021 after serving as a Senior Advisor to the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. He served in this role through two administrations and the COVID-19 pandemic. He also maintained his...
Matthew G. Clark, Joint Project Manager, CBRN Medical,
JPEO-CBRND
Colonel Matthew G. Clark is the Joint Project Manager for Chemical, Biological,Radiological, and Nuclear Medical (JPM CBRN Medical). He is responsible for leading themedical portfolio for the Joint Program Executive Office for Chemical, Biological,Radiological and Nuclear Defense (JPEO-CBRND).COL...
Shirit Einav, Associate Professor of Medicine,
Stanford University
Dr Shirit Einav received an M.D. from Tel-Aviv University, Israel. She completed her residency in Internal Medicine at the Beth Israel Deaconess Medical Center (Harvard Medical School) followed by fellowship in Infectious Diseases at Stanford, then pursued a research postdoctoral fellowship at...
Dr Jeff Stein, President and Chief Executive Officer,
Cidara Therapeutics
Dr. Stein has been President, CEO and Director of Cidara since January 2014. Previously he was CEO of Trius Therapeutics, Inc. from 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received...
Kevin Killeen, CSO,
Matrivax
Dr. Killeen joined Matrivax as Chief Scientific Officer in 2009. He has extensive training in the fields of vaccinology, molecular biology, microbiology, protein chemistry, and immunology. Dr Killeen’s experience includes identifying and leading the in-licensing effort of the rotavirus vaccine...
Liz Wu, Director, Early Innovation Partnering,
Johnson & Johnson Innovation
Liz is Director, Early Innovation Partnering at Johnson & Johnson Innovation, California. In this role, she focuses on pharmaceutical innovation in support of the immunology and cardiovascular & metabolism businesses. Her charge is to identify licensing, collaboration, and investment...
Dr Aeron Hurt, Principal Global Medical Science Director, Influenza and COVID-19,
Roche
Dr. Aeron Hurt is the Principal Global Medical Director, for both COVID-19 and Influenza at Roche, Basel, Switzerland. Aeron was previously Head of the Antiviral Susceptibility Analysis Surveillance Unit and Research group at the WHO Collaborating Centre for Reference and Research on...
Dr Andrew Vaillant, Chief Scientific Officer,
Replicor Inc.
Dr. Vaillant is the Chief Scientific Officer at Replicor Inc. He has more than 20 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of Replicor’s nucleic acid polymer (NAP) technology. Dr. Vaillant has authored numerous primary...
Neeraj Kapoor, Director, Scientific Leader, Group A Strep and Periodontitis Vaccine Programs,
Vaxcyte
Expert protein biochemist with more that 10 years of experience in generating proteins using both cell based (E.coli, Sf9, mammalian) or XpressCF+TM cell free protein synthesis systems. He is currently leading efforts towards progressing a Group A Strep vaccine towards a human clinical trial.
Barry Datlof, Chief, Business Development and Commercialization,
U.S. Army Medical Research and Development Command
Mr. Datlof is the Chief, Business Development and Commercialization in the Office of Medical Technology Transfer at the U.S. Army Medical Research and Materiel Command. He has commercialized biomedical and IT technologies in the university, nonprofit, for-profit, and government sectors. He owns...
John Flaherty, Executive Director, Virology Clinical Development,
Gilead Science
Dr Flaherty received his Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy, after which he completed a clinical residency and Infectious Diseases fellowship at the University of California at San Francisco (UCSF). After serving as a clinical faculty member at...
Len Yaffe, MD,
Stoc*Doc Partners
Len Yaffe was the first MD to transition to Wall Street as an analyst many decades ago. He worked primarily at Montgomery Securities in San Francisco, and was recognized as a top analyst in pharmaceuticals, medical devices and drug distribution. He was early in recognizing the impact of intraocular ...
Terrence Stull, President,
BacVax
Terrence L. Stull, M.D., is President of BacVax. He is responsible for the administrative and scientific direction of BacVax’s development of Bacterial Vaccine Polypeptides. His education and training include his M.D. from the University of Birmingham in Alabama, residency training at Stanford, and ...
Dr Seth Lederman, Co-Founder, Chief Executive Officer & Chairman,
Tonix Pharmaceuticals
Seth Lederman is CEO of Tonix Pharmaceuticals. Prior to Tonix, and his career in Biotech, Dr. Lederman served as tenured Associate Professor at Columbia University and directed basic science research in molecular immunology, infectious diseases and the development of therapeutics for autoimmune...
Sam Lee, President,
Cocrystal Pharma, Inc.
Sam Lee, Ph.D., is President, Interim Co-CEO and co-founder of Cocrystal Pharma Inc., Bothell, Washington, founded in 2007. Cocrystal Pharma Inc. (NASDAQ: COCP) is developing novel small molecule antivirals for the treatment of COVID-19, Influenza, Norovirus, and Hepatitis C. He served on the...
Dr Andrew Vaillant, Chief Scientific Officer,
Replicor Inc.
Dr. Vaillant is the Chief Scientific Officer at Replicor Inc. He has more than 20 years of experience in the fields of nucleic acid chemistry, virology and drug development and is the discoverer of Replicor’s nucleic acid polymer (NAP) technology. Dr. Vaillant has authored numerous primary...
Ali Fattom, Sr. Vaccine R&D Consultant,
Blue Water Vaccines
Dr Fattom has a PhD in microbiology. He spent 5 years at John Robbins lab at the NIH working on polysaccharide conjugate vaccines. He served as sr. VP for vaccine R&D at Nabi Biopharmaceutical. Previous CSO at BlueWilow leading the effort developing viral vaccines including HSV, RSV, and...
Peter Goldstein, Executive Director, Vaccine Platform Development,
Iliad Biotechnologies
Peter Goldstein, Executive Director of Vaccine Platform Development. Peter has 18 years of experience managing multidisciplinary scientific and technical programs. He plays a central role in management of ILiAD’s assay development, clinical serology, and Quality Management System, and is...
Dr Aeron Hurt, Principal Global Medical Science Director, Influenza and COVID-19,
Roche
Dr. Aeron Hurt is the Principal Global Medical Director, for both COVID-19 and Influenza at Roche, Basel, Switzerland. Aeron was previously Head of the Antiviral Susceptibility Analysis Surveillance Unit and Research group at the WHO Collaborating Centre for Reference and Research on...
Paul Duffin, Sr. Manager, Product Development,
Emergent Biosolutions
R. Paul Duffin is a Senior Manager of Drug Product Development at Emergent BioSolutions, and has worked extensively on the development and clinical preparation of the CVD 103-HgR Cholera vaccine.
Pravin Kaumaya, Professor and Director Vaccine Research,
The Ohio State University Werner Medical Center
Kaumaya is Professor of Medicine in Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer, viral diseases as well as...
Timur Yarovinsky, VP of Discovery, Director of Immunology,
CaroGen Corporation
Dr. Timur Yarovinsky is Vice President of Discovery at CaroGen Corporation. Prior to CaroGen, Dr. Yarovinsky worked as a Research Scientist at Yale University and the University of Iowa. He holds M.D. and Ph.D. from Russian State Medical University.
M Javad Aman, President and Chief Scientific Officer,
Integrated BioTherapeutics
Javad Aman has been the President and Chief Scientific Officer (CSO) of Integrated BioTherapeutics, Inc. (IBT), a US biotechnology company focused on the discovery of vaccines and immunotherapeutics for emerging infectious diseases. Since 2007, he has led a group of 40 people working on several...
Khursheed Anwer, Executive Vice President & Chief Scientific Officer,
Imunon, Inc.
Khursheed Anwer, PhD, MBA, assumed the title of Executive Vice President and Chief Science Officer, upon Celsion’s June 2014 acquisition of EGEN, Inc., where he was President and Chief Science Officer, a position he held since 2009. He joined EGEN, Inc. in July, 2002, as Vice President of Research...
Edward Pham, Deputy Director Translational Research, ViRx@Stanford, Instructor in Medicine,
Stanford University
Dr. Edward Pham is an instructor in medicine (Division of Gastroenterology and Hepatology) at Stanford University School of Medicine. He is also the deputy director for translational research of ViRx@Stanford, the Stanford Biosecurity and Pandemic Preparedness Initiative, which focuses on...
Barbara Franklin, Director,
All One Communication
Barbara A.K. Franklin, PhD is Owner/Director of All One Communication. As a specialist in communication for health and development, she has worked worldwide for 30 years supporting United Nations agencies, multilateral, bilateral, NGO and national teams in communication for change. She often works ...
Scott Hamilton Kennedy, Director,
Black Valley Films
Academy Award nominee Scott Hamilton Kennedy is a writer, director, producer, cameraman, and editor and has worked on everything from music videos and commercials to motion capture animation, scripted and reality television, and fiction and non-fiction film.
